Analyst Scoreboard: 6 Ratings For QuidelOrtho
Portfolio Pulse from Benzinga Insights
QuidelOrtho (NASDAQ:QDEL) has received mixed analyst ratings over the past three months, with a notable shift towards a bearish outlook in the last 30 days. The average 12-month price target has been lowered to $73.00 from $100.17, indicating a 27.12% decrease. Analysts from firms including UBS, RBC Capital, Raymond James, JP Morgan, and Citigroup have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Despite a slight decline in revenue growth, QuidelOrtho maintains strong financial health with exceptional net margin, ROE, and ROA, and a sound debt management strategy.
March 04, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
QuidelOrtho has seen a bearish shift in analyst ratings with a significant decrease in the average 12-month price target. Despite this, the company exhibits strong financial health with high net margin, ROE, and ROA.
The bearish shift in analyst ratings and the decrease in the average 12-month price target suggest a short-term negative impact on QDEL's stock price. However, the company's strong financial metrics may mitigate some of the negative sentiment, indicating a complex short-term outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100